Q1 Earnings Estimate for Geron Issued By B. Riley

Geron Co. (NASDAQ:GERN) – Research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Geron in a research report issued to clients and investors on Wednesday, February 26th. B. Riley analyst K. Patel anticipates that the biopharmaceutical company will earn ($0.03) per share for the quarter. B. Riley currently has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC cut their price target on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday. Stifel Nicolaus cut their price target on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Barclays reissued an “overweight” rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a research note on Thursday. Finally, Scotiabank cut their target price on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Price Performance

NASDAQ:GERN opened at $1.76 on Friday. Geron has a one year low of $1.46 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The stock has a market cap of $1.06 billion, a PE ratio of -5.50 and a beta of 0.53. The stock has a 50 day moving average price of $2.97 and a 200 day moving average price of $3.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in shares of Geron during the fourth quarter worth $28,000. Integrated Wealth Concepts LLC purchased a new position in shares of Geron during the fourth quarter worth $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Geron during the fourth quarter worth $45,000. Readystate Asset Management LP purchased a new position in shares of Geron during the third quarter worth $58,000. Finally, Rovin Capital UT ADV purchased a new position in Geron in the third quarter valued at $62,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.